NCT00724698已完成不适用
Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Tablet Among Filipino Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,011
- 主要终点
- Adverse Events
研究概览
简要总结
Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatient men or women, age 12 years and above.
- •Diagnosis of Allergic Rhinitis or Chronic Idiopathic Urticaria
排除标准
- •Known hypersensitivity to Desloratadine.
- •Pregnancy or lactation
研究组 & 干预措施
Group
Patients diagnosed with Allergic Rhinitis or Chronic Idiopathic Urticaria
干预措施: Desloratadine (Drug)
结局指标
主要结局
Adverse Events
时间窗: Final Visit (Day 15)
Number of adverse events reported
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)Rhinitis, Allergic, SeasonalRhinitis, Allergic, PerennialUrticariaNCT00761527Organon and Co2,980
已完成
3 期
Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)AtopyChronic Idiopathic UrticariaNCT00757562Organon and Co97
已完成
4 期
Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)Allergic Airway DiseaseNCT00779636Organon and Co506
已完成
不适用
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)Overactive BladderNCT01488578Pfizer's Upjohn has merged with Mylan to form Viatris Inc.11,157
已完成
不适用
Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)RhinitisNCT00704769Organon and Co591